Audio Interview

Oxford/AstraZeneca COVID-19 vaccine trial: adverse patient event reports

Published on November 18, 2020   14 min

Other Talks in the Series: Interviews on Covid-19

0:00
Interviewer: Professor Saad Shakir, thank you very much for taking the time to do this interview with us today to discuss the occurrence of an adverse event reported in a patient in the Oxford University and AstraZeneca clinical trial for their new COVID-19 vaccine earlier this year. Let me start by asking about first of all, can you tell us a little bit about this specific vaccine just as a quick introduction, and in particular regarding what is known of its mode of action and projected safety profile? Prof. Shakir: Thank you. The Oxford AstraZeneca vaccine is a new platform where a DNA adenovirus introduces the DNA, the sequence of a protein of the well-known spikes of the COVID-19 virus, which gets transcribed to the messenger RNA. Thus, it uses the cells natural machinery to produce the spike protein antigen of SARS COVID-2. This is a technology which is used to introduce genetic materials into human cells, because if you inject DNA on its own, it wouldn't get into the cell. When these proteins are released into the bloodstream, the human body then will produce an immune response to these proteins by way of antibodies and cellular response,
Hide

Oxford/AstraZeneca COVID-19 vaccine trial: adverse patient event reports

Embed in course/own notes